Centaurus Financial, Inc. Biogen Inc. Transaction History

Centaurus Financial, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$223.92 - $287.77 $90,463 - $116,259	-404 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $28,299 - $36,905	-100 Reduced 19.84%	404 $114,000
Q1 2021 Apr 30, 2021	BUY	$242.95 - $284.63 $122,446 - $143,453	504 New	504 $141,000
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $100,877 - $116,475	-381 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $98,549 - $130,511	381 New	381 $102,000
Q1 2020 Apr 21, 2020	SELL	$268.85 - $341.04 $179,322 - $227,473	-667 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$220.06 - $304.07 $146,780 - $202,814	667 New	667 $198,000
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $95,238 - $106,819	-438 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$219.29 - $241.72 $73,242 - $80,734	334 Added 321.15%	438 $102,000
Q1 2019 Jul 01, 2019	SELL	$216.71 - $338.96 $72,381 - $113,212	-334 Reduced 76.26%	104 $438,000
Q1 2019 May 13, 2019	BUY	$216.71 - $338.96 $94,918 - $148,464	438 New	438 $104,000
Q3 2018 Nov 05, 2018	SELL	$293.51 - $383.83 $30,525 - $39,918	-104 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$257.52 - $306.91 $26,782 - $31,918	104 New	104 $30,000

1,032

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.